This study consists of 3 treatment periods as below. For Treatment A and Treatment B, single- and multiple-dose stages are included.~Treatment A:~One tablet of IBUMR will be administered to the subjects under fasted condition, followed by a minimum of 72-hour washout interval. After the washout period, subjects will receive 1 × IBUMR every 12 hours for a total of 8 doses.~Treatment B:~One tablet of IBURed-800mg will be administered to the subjects under fasted condition, followed by a minimum of 72-hour washout interval. After the washout period, subjects will receive 1 × IBURed-600mg every 8 hours for a total of 12 doses.~Treatment C:~Single dose of IBUMR will be given to the subjects under fed condition (a standard high-fat, high calorie breakfast should be consumed within 30 minutes prior to dosing).~A minimum of 3-day washout interval will be introduced across the 3 treatment periods. Subjects will be required to be fasted for at least 10 hours prior to the administration of morning doses.
An open-label, randomized, 3-way crossover study to evaluate the pharmacokinetics of investigational product Ibuprofen Modified-Release Tablets 800 mg in comparison to the reference standard Ibuprofen Regular-Release Tablets 600 mg/800 mg in normal healthy volunteers~Primary objective:~To evaluate the food effect of IBUMR and its bioavailability of single and multiple doses compared with reference drugs in normal healthy volunteers.~Secondary objectives:~To determine and compare the single and multiple dose PK profiles of IBUMR and reference drugs.~To identify the effect duration for IBUMR after dose administration by detecting ibuprofen concentrations in plasma.~To evaluate the safety profile of single and multiple doses of IBUMR.